Rigel Pharmaceuticals | RIGL - Debt


Rigel Pharmaceuticals reported $59.69M in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 54.6B 17M Dec/2025
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 312.77M 53.52M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Celldex Therapeutics USD 2.34M 285K Dec/2025
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 451.49M 494K Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Veracyte USD 39.65M 799K Dec/2025